Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Sep 25, 2024
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding Nemolizumab (Data Presentation at European Academy of Dermatology and Venereology)
TOKYO, September 25, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release today about data presentation on nemolizumab at the 2024 European Academy of Dermatology and Venereology (EADV) congress. Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentationshttps://www.galderma.com/news/eadv-2024-late-breaking-news-sessions-new-galderma-data-demonstrating-nemolizumabs-long-term
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
